Marshall Edwards raises $10M; Investors buy stake in ThromboGenics;

> Marshall Edwards has raised $10 million through the sale of stock to Novogen and OppenheimerFunds. The company is advancing new cancer therapies. Release

> A group of private investors have purchased an eight percent interest in ThromboGenics. The interest was acquired from Biggar, which will retain a 9.8 percent share of the developer. Report

> GenVec will receive up to $6.6 million of federal funding to develop vaccines to prevent foot-and-mouth disease. Report 

> The FDA has provided final approval for Noven's Stavzor, a therapy for use against bipolar disorder, seizures and migraine headaches. Noven release

> A pair of FDA critics, Rep. John Dingell (D, MI) and Sen. Chuck Grassley (R, IA), are making it a major priority to overhaul the FDA and give the organization additional power, as well as to draw a deeper line in the sand between the agency and the industry it regulates. Report

> A generic version of Depakote, an anti-seizure medication that clinicians also use to treat migraine headaches and bipolar disorder, received FDA approval yesterday. Report

> Although there weren't any obvious thugs or smugglers--and in fact no criminal action will occur--the feds were busy yesterday seizing $24 million in drugs from KV Pharmaceutical. Report

> Barr Pharmaceuticals confirmed that its subsidiary, Barr Laboratories, will go head to head with Amgen in a patent challenge process under the Hatch-Waxman Act. Report

And Finally... Researchers say that the number of deaths from medication errors at home has soared over the past 25 years. Story

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.